What is ENvue Medical's earnings per share (EPS)?

ENvue Medical (FEED) reported diluted earnings per share of $-26.69 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

ENvue Medical Financials

FEED

Source SEC Filings (10-K/10-Q) Updated Apr 15, 2026 Currency USD FYE April

This page shows ENvue Medical (FEED) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Earnings Quality Low Quality

0.52x

For every $1 of reported earnings, ENvue Medical generates $0.52 in operating cash flow (-$9.4M OCF vs -$18.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$2.6M

YoY-0.2%

5Y CAGR+32.6%

10Y CAGR+33.0%

ENvue Medical generated $2.6M in revenue in fiscal year 2025. This represents a decrease of 0.2% from the prior year.

EBITDA

-$22.0M

YoY-514.1%

ENvue Medical's EBITDA was -$22.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 514.1% from the prior year.

Net Income

-$18.2M

YoY-390.8%

ENvue Medical reported -$18.2M in net income in fiscal year 2025. This represents a decrease of 390.8% from the prior year.

EPS (Diluted)

$-26.69

ENvue Medical earned $-26.69 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 94.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$9.4M

YoY-274.4%

ENvue Medical generated -$9.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 274.4% from the prior year.

Cash & Debt

N/A

Dividends Per Share

N/A

Shares Outstanding

ENvue Medical had 4M shares outstanding in fiscal year 2025. This represents an increase of 9666.5% from the prior year.

Margins & Returns

Gross Margin

6.0%

YoY-53.0pp

5Y CAGR-28.4pp

10Y CAGR-60.7pp

ENvue Medical's gross margin was 6.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 53.0 percentage points from the prior year.

Operating Margin

-896.6%

YoY-756.5pp

5Y CAGR-139.1pp

10Y CAGR+72.2pp

ENvue Medical's operating margin was -896.6% in fiscal year 2025, reflecting core business profitability. This is down 756.5 percentage points from the prior year.

Net Margin

-712.3%

YoY-567.5pp

5Y CAGR-17.9pp

10Y CAGR+1249.6pp

ENvue Medical's net profit margin was -712.3% in fiscal year 2025, showing the share of revenue converted to profit. This is down 567.5 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

$1.8M

YoY+93.8%

5Y CAGR+59.4%

10Y CAGR+16.0%

ENvue Medical invested $1.8M in research and development in fiscal year 2025. This represents an increase of 93.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$60K

YoY+1900.0%

5Y CAGR+97.4%

10Y CAGR+50.6%

ENvue Medical invested $60K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 1900.0% from the prior year.

FEED Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$2.6M-0.2%	$2.6M+12.0%	$2.3M+203.6%	$752K-55.6%	$1.7M+172.1%	$623K
Cost of Revenue	$2.4M+128.6%	$1.1M+40.8%	$746K+27.5%	$585K-36.8%	$925K+126.2%	$409K
Gross Profit	$153K-89.9%	$1.5M-1.9%	$1.5M+820.4%	$167K-78.3%	$770K+259.8%	$214K
R&D Expenses	$1.8M+93.8%	$909K+391.4%	$185K-34.6%	$283K-3.4%	$293K+71.3%	$171K
SG&A Expenses	$7.6M+120.5%	$3.5M-11.8%	$3.9M-0.2%	$3.9M-22.3%	$5.1M+34.2%	$3.8M
Operating Income	-$22.9M-539.0%	-$3.6M-4.2%	-$3.4M+31.4%	-$5.0M+11.8%	-$5.7M-20.4%	-$4.7M
Interest Expense	N/A	$135K0.0%	$135K-61.1%	$347K	N/A	$147K
Income Tax	-$307K-1715.8%	$19K-34.5%	$29K-17.1%	$35K+9.4%	$32K+113.3%	$15K
Net Income	-$18.2M-390.8%	-$3.7M+0.2%	-$3.7M+31.9%	-$5.4M+61.9%	-$14.3M-230.1%	-$4.3M
EPS (Diluted)	$-26.69	$-13.73	$-23.32-507.3%	$-3.84	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$722K+46.2%	$494K-51.8%	$1.0M+130.9%	$444K+18.1%	$376K-54.0%	$817K-11.3%	$921K-21.8%	$1.2M
Cost of Revenue	$533K+0.8%	$529K-19.4%	$656K+307.5%	$161K-33.7%	$243K-37.5%	$389K+51.4%	$257K-41.6%	$440K
Gross Profit	$189K+640.0%	-$35K-109.5%	$369K+30.4%	$283K+112.8%	$133K-68.9%	$428K-35.5%	$664K-9.9%	$737K
R&D Expenses	$221K-77.3%	$972K+83.4%	$530K+50.6%	$352K+41.4%	$249K+33.2%	$187K+54.5%	$121K+95.2%	$62K
SG&A Expenses	$1.4M-37.7%	$2.3M+67.8%	$1.3M+19.2%	$1.1M+67.3%	$673K-6.0%	$716K-24.3%	$946K-17.3%	$1.1M
Operating Income	-$2.2M+43.5%	-$4.0M-114.7%	-$1.9M-35.2%	-$1.4M-41.2%	-$970K-43.9%	-$674K-18.7%	-$568K+19.1%	-$702K
Interest Expense	$53K-63.2%	$144K+171.7%	$53K+55.9%	$34K+3.0%	$33K-2.9%	$34K0.0%	$34K+3.0%	$33K
Income Tax	$35K-43.5%	$62K+313.3%	$15K+200.0%	$5K+66.7%	$3K-25.0%	$4K-42.9%	$7K-36.4%	$11K
Net Income	$510K+112.8%	-$4.0M-59.2%	-$2.5M-74.4%	-$1.4M-43.4%	-$998K-45.1%	-$688K-17.0%	-$588K+27.7%	-$813K
EPS (Diluted)	$-0.91	$-1.03	$3.98	N/A	$-3.56+86.9%	$-27.18-1242.0%	$2.38	N/A

FEED Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	N/A	$3.6M-45.6%	$6.7M+13.5%	$5.9M-31.8%	$8.6M+4.8%	$8.2M
Current Assets	N/A	$3.3M-48.7%	$6.5M+15.7%	$5.6M-32.8%	$8.3M+4.7%	$8.0M
Cash & Equivalents	N/A	$752K-77.1%	$3.3M+21.0%	$2.7M-64.9%	$7.7M+8.3%	$7.1M
Inventory	N/A	$2.2M-19.8%	$2.7M+25.6%	$2.2M+1142.9%	$175K+20.7%	$145K
Accounts Receivable	N/A	$98K-69.2%	$318K+3433.3%	$9K-95.5%	$200K+700.0%	$25K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	$3.0M+11.8%	$2.7M+1.5%	$2.6M+14.6%	$2.3M-60.4%	$5.8M
Current Liabilities	N/A	$2.7M+10.9%	$2.5M+6.0%	$2.3M+21.7%	$1.9M-34.4%	$2.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	N/A	$627K-84.3%	$4.0M+23.4%	$3.2M-48.8%	$6.3M+163.7%	$2.4M
Retained Earnings	N/A	-$69.8M-5.6%	-$66.1M-5.9%	-$62.4M-9.6%	-$56.9M-33.5%	-$42.7M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$54.4M+5.6%	$51.5M+16.7%	$44.1M+1115.3%	$3.6M-22.5%	$4.7M-17.8%	$5.7M-8.6%	$6.2M-6.6%	$6.7M
Current Assets	$10.0M+45.3%	$6.9M+78.6%	$3.9M+15.9%	$3.3M-23.9%	$4.4M-18.7%	$5.4M-9.4%	$5.9M-8.4%	$6.5M
Cash & Equivalents	$7.0M+72.5%	$4.0M+570.5%	$601K-20.1%	$752K-42.4%	$1.3M-39.9%	$2.2M-19.6%	$2.7M-17.8%	$3.3M
Inventory	$2.2M+1.7%	$2.2M+9.3%	$2.0M-7.9%	$2.2M-2.6%	$2.3M-7.4%	$2.4M-6.1%	$2.6M-5.3%	$2.7M
Accounts Receivable	$252K+119.1%	$115K-67.9%	$358K+265.3%	$98K-83.1%	$580K+18.6%	$489K+35.8%	$360K+13.2%	$318K
Goodwill	$38.6M0.0%	$38.6M+13.9%	$33.9M	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$11.9M+8.3%	$11.0M+30.5%	$8.4M+180.8%	$3.0M+6.8%	$2.8M-1.6%	$2.9M+4.5%	$2.7M+1.7%	$2.7M
Current Liabilities	$11.6M+78.0%	$6.5M-20.2%	$8.2M+201.2%	$2.7M+8.0%	$2.5M-1.4%	$2.6M+5.3%	$2.4M-1.1%	$2.5M
Long-Term Debt	N/A	N/A	$1.3M	N/A	N/A	N/A	N/A	N/A
Total Equity	$42.5M+4.9%	$40.5M+13.5%	$35.7M+5589.8%	$627K-66.5%	$1.9M-34.1%	$2.8M-18.9%	$3.5M-12.1%	$4.0M
Retained Earnings	-$76.9M-1.1%	-$76.0M-5.1%	-$72.3M-3.6%	-$69.8M-2.1%	-$68.4M-1.5%	-$67.4M-1.0%	-$66.7M-0.9%	-$66.1M

FEED Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$9.4M-272.5%	-$2.5M+30.1%	-$3.6M+48.8%	-$7.0M-61.1%	-$4.4M-28.8%	-$3.4M
Capital Expenditures	$60K+1900.0%	$3K+200.0%	$1K-66.7%	$3K0.0%	$3K+50.0%	$2K
Free Cash Flow	-$9.4M-274.4%	-$2.5M+30.1%	-$3.6M+48.8%	-$7.0M-61.1%	-$4.4M-28.8%	-$3.4M
Investing Cash Flow	$88K+3033.3%	-$3K-200.0%	-$1K+66.7%	-$3K0.0%	-$3K-50.0%	-$2K
Financing Cash Flow	$12.8M+1278500.0%	$1K-100.0%	$4.2M+101.8%	$2.1M-54.3%	$4.6M-51.9%	$9.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$2.0M+41.8%	-$3.4M-151.9%	-$1.3M-145.1%	-$548K+34.4%	-$836K-51.2%	-$553K+4.5%	-$579K-17.9%	-$491K
Capital Expenditures	$28K+600.0%	$4K-20.0%	$5K	$0	$0-100.0%	$2K+100.0%	$1K	$0
Free Cash Flow	-$2.0M+41.0%	-$3.4M-151.3%	-$1.3M-146.0%	-$548K+34.4%	-$836K-50.6%	-$555K+4.3%	-$580K-18.1%	-$491K
Investing Cash Flow	-$28K-600.0%	-$4K-102.8%	$143K	$0	$0+100.0%	-$2K-100.0%	-$1K	$0
Financing Cash Flow	$4.9M-28.2%	$6.8M+552.4%	$1.1M	$0+100.0%	-$27K	N/A	N/A	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

FEED Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	6.0%-53.0pp	59.0%-8.4pp	67.3%+45.1pp	22.2%-23.2pp	45.4%+11.1pp	34.4%
Operating Margin	-896.6%-756.5pp	-140.0%+10.5pp	-150.5%+516.0pp	-666.5%-331.2pp	-335.3%+422.2pp	-757.5%
Net Margin	-712.3%-567.5pp	-144.8%+17.7pp	-162.5%+561.9pp	-724.5%+118.1pp	-842.6%-148.2pp	-694.4%
Return on Equity	N/A	-590.9%-497.9pp	-93.0%+75.5pp	-168.5%+57.7pp	-226.2%-45.5pp	-180.7%
Return on Assets	N/A	-102.1%-46.5pp	-55.6%+37.1pp	-92.7%+73.0pp	-165.7%-113.1pp	-52.6%
Current Ratio	N/A	1.22-1.4	2.64+0.2	2.42-2.0	4.38+1.6	2.75
Debt-to-Equity	N/A	4.79+4.1	0.67-0.1	0.82+0.5	0.37-2.1	2.44
FCF Margin	-369.4%-271.0pp	-98.5%+59.3pp	-157.8%+778.1pp	-935.9%-678.1pp	-257.8%+286.8pp	-544.6%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	26.2%+33.3pp	-7.1%-43.1pp	36.0%-27.7pp	63.7%+28.4pp	35.4%-17.0pp	52.4%-19.7pp	72.1%+9.5pp	62.6%
Operating Margin	-311.2%+493.6pp	-804.9%-624.2pp	-180.7%+127.9pp	-308.6%-50.6pp	-258.0%-175.5pp	-82.5%-20.8pp	-61.7%-2.0pp	-59.6%
Net Margin	70.6%+874.5pp	-803.9%-560.4pp	-243.4%+78.9pp	-322.3%-56.9pp	-265.4%-181.2pp	-84.2%-20.4pp	-63.8%+5.2pp	-69.1%
Return on Equity	1.2%+11.0pp	-9.8%-2.8pp	-7.0%+221.2pp	-228.2%-174.9pp	-53.3%-29.1pp	-24.2%-7.4pp	-16.8%+3.6pp	-20.4%
Return on Assets	0.9%+8.7pp	-7.7%-2.1pp	-5.7%+33.8pp	-39.4%-18.1pp	-21.3%-9.2pp	-12.1%-2.7pp	-9.4%+2.8pp	-12.2%
Current Ratio	0.86-0.2	1.05+0.6	0.47-0.8	1.22-0.5	1.74-0.4	2.11-0.3	2.45-0.2	2.64
Debt-to-Equity	0.280.0	0.27+0.2	0.04-4.8	4.79+3.3	1.50+0.5	1.00+0.2	0.78+0.1	0.67
FCF Margin	-276.7%+408.9pp	-685.6%-554.1pp	-131.5%-8.1pp	-123.4%+98.9pp	-222.3%-154.4pp	-67.9%-4.9pp	-63.0%-21.3pp	-41.7%

Frequently Asked Questions

What is ENvue Medical's annual revenue?

ENvue Medical (FEED) reported $2.6M in total revenue for fiscal year 2025. This represents a -0.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is ENvue Medical's revenue growing?

ENvue Medical (FEED) revenue declined by 0.2% year-over-year, from $2.6M to $2.6M in fiscal year 2025.

Is ENvue Medical profitable?

No, ENvue Medical (FEED) reported a net income of -$18.2M in fiscal year 2025, with a net profit margin of -712.3%.

What is ENvue Medical's EBITDA?

ENvue Medical (FEED) had EBITDA of -$22.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is ENvue Medical's gross margin?

ENvue Medical (FEED) had a gross margin of 6.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is ENvue Medical's operating margin?

ENvue Medical (FEED) had an operating margin of -896.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is ENvue Medical's net profit margin?

ENvue Medical (FEED) had a net profit margin of -712.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is ENvue Medical's free cash flow?

ENvue Medical (FEED) generated -$9.4M in free cash flow during fiscal year 2025. This represents a -274.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is ENvue Medical's operating cash flow?

ENvue Medical (FEED) generated -$9.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are ENvue Medical's capital expenditures?

ENvue Medical (FEED) invested $60K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does ENvue Medical spend on research and development?

ENvue Medical (FEED) invested $1.8M in research and development during fiscal year 2025.

How many shares does ENvue Medical have outstanding?

ENvue Medical (FEED) had 4M shares outstanding as of fiscal year 2025.

Are ENvue Medical's earnings high quality?

ENvue Medical (FEED) has an earnings quality ratio of 0.52x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.